Target intelligence / Profile preview

Calcium hydroxyapatite (HAp)

Target
HAp
Molecular classification
Other
01

Overview

Calcium hydroxyapatite is the primary inorganic mineral constituent of vertebrate bones and dental enamel, representing approximately 97% of enamel by weight and 70% of dentin. It provides essential structural rigidity, hardness, and load-bearing capacity to the skeletal and dental systems. In clinical medicine and dentistry, hydroxyapatite serves as a critical therapeutic target for managing bone resorption disorders and dental decay. Bisphosphonates, such as zoledronic acid and alendronate, exhibit an extremely high affinity for hydroxyapatite, binding to the mineral surface to concentrate in bone tissue where they subsequently inhibit osteoclast activity and reduce bone turnover. In oral care, fluoride ions interact with hydroxyapatite to substitute hydroxyl groups, forming fluorapatite, which is significantly more resistant to acid-mediated demineralization. Additionally, biomimetic synthetic hydroxyapatite and enamel-targeting peptides are utilized in remineralizing toothpastes and therapies to physically deposit calcium and phosphate back into microscopic enamel defects, restoring mineral density and reducing dentin hypersensitivity.

Other names
HydroxyapatiteDurapatiteBone mineralEnamel mineralCalcium phosphate hydroxideTribasic calcium phosphate
02

Mechanism of action

Bisphosphonates adsorb to calcium hydroxyapatite to target bone tissue and inhibit osteoclast-mediated bone resorption. Fluoride ions substitute hydroxyl groups in the hydroxyapatite lattice to form acid-resistant fluorapatite. Biomimetic peptides and synthetic hydroxyapatite deposit calcium and phosphate directly onto demineralized enamel surfaces to restore mineral density and seal dentinal tubules.

03

Biological functions

Bone mineralizationStructural supportEnamel protectionCalcium homeostasisPhosphate homeostasisOther
04

Disease associations

OsteoporosisDental cariesPaget's disease of boneBone metastasisHypercalcemia of malignancyOther
05

Safety considerations

Osteonecrosis of the jaw (ONJ)Atypical femoral fractures (AFF)Dental fluorosisSkeletal fluorosisTetracycline-induced tooth discolorationHypocalcemia
06

Interacting drugs

13 more in the full profile.

07

Biomarkers

Bone mineral density (BMD)Serum calciumSerum phosphateEnamel microhardnessC-terminal telopeptide of type I collagen (CTX)Bone-specific alkaline phosphatase (BSAP)

Beyond the preview

Go deeper on Calcium hydroxyapatite (HAp).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcium hydroxyapatite (HAp).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call